Innovation Pharmaceuticals Inc (IPIX)

[KMBJN]

What a crazy set of confusing rules / guidelines / "tips" for posters and abstracts:

http://am.asco.org/call-abstracts

"What is acceptable in a Trials in Progress abstract and poster?

Scientific background/rationale for the trial. Preclinical and/or earlier-phase clinical data that has already been publically presented or published may be included with references. The Trials in Progress session should not be used to present preclinical or earlier-phase clinical data for the first time.
Trial design and statistical methods, highlighting any novel aspects of the design
Treatment or intervention planned
Major eligibility criteria, highlighting unusual aspects
Correlative studies of particular interest
Current enrollment without providing results or endpoints
Enrollment must have already begun or have been completed with no data analysis available by the submission deadline (February 3, 2015).
Phase I studies may say, “Cohorts 1 and 2 have been completed without DLT. Enrollment to cohort 3 began in January 2015.”
Phase II studies may report, “8 of planned 32 patients have been enrolled” or “Prespecified activity goal for the first stage of accrual was met; second stage accrual began in January 2015.”
Phase III trials may report, “The DMC last reviewed the trial in December 2014 and suggested that the trial continue as planned.”
Clinical trial registry number (required)

What is not acceptable in a Trials in Progress abstract?

Any preliminary data including toxicity, response rate, pharmacokinetic, or correlative analyses. NOTE: Abstracts including results or preliminary data will be rejected without further review.
Proprietary drug names"



From your link,

"The 2015 ASCO Annual Meeting
TIPS FOR CREATING YOUR POSTER

Trials in Progress Posters

Do not include any preliminary data including toxicity,
response rate, pharmacokinetic, or correlative
analyses."

from previous link seems only to apply to abstracts, but listed here on this site as applying to "posters."


Hard to think these are hard rules, as clearly we use the (apparently, but again not clearly) proprietary name "Kevetrin" 12 times in the abstract, and certainly they are presenting "preliminary data" in that they only show the p21 results for 31 / 40 enrolled subjects (out of perhaps up to 60 that will eventually be enrolled).

I think there must be lots of gray areas in these rules / tips ...

Just like the Nasdaq listing rules